Pixium Vision announces the publication of a paper in Nature Communications, outlining further data with its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophic dry age-related macular degeneration (AMD).
“The peer-reviewed publication of these data in the prestigious journal of Nature Communications demonstrates the validation by our peers of the highly innovative and promising nature of our Prima System for the treatment of dry AMD,” said Lloyd Diamond, CEO of Pixium Vision. “The data highlighted in this publication not only support that patients can combine their remaining peripheral vision with our bionic vision, that the resolution of perception is close to the resolution of the implant, and also very importantly exhibit that the natural peripheral vision is not reduced over time following the implantation. The pivotal PRIMAvera study is ongoing in Europe and we look forward to demonstrating these great benefits in a larger pool of patients, targeting to bring the Prima System to the European market in 2024”.